All News
Study Reassures on HCQ Heart Risks in Rheumatoid Arthritis
d
MedPage Today
Among U.S. veterans receiving hydroxychloroquine (HCQ) as long-term therapy for rheumatoid arthritis, development of long QT syndrome was rare and not markedly more common compared with similar patients treated with other agents, researchers said.
Read Article
Voclosporin Efficacy and Safety in Lupus Nephritis
An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year.
Read Article
ACR RISE Registry, 9,560 gout pts- ONLY 56% of patients had > = one Serum Urate recorded during the year; amongst those w/ 1 SU recorded, 74% achieved the SU target. ONLY HALF? GETTING SUAs? Are we not Rheums? https://t.co/OfKRWtyjBT https://t.co/8kjwEVZwB3
Links:
Dr. John Cush RheumNow ( View Tweet)
Multicentre matched control study looked at primary Sjogrens that developed lymphoma or NOT. Parotid swelling (PSW) is an early major predictor of non-Hodgkin lymphoma in pSS; esp if present before or dx, & w/ a longer duration of PSW https://t.co/QokXF6klEv https://t.co/YqFgAqt4ku
Links:
Dr. John Cush RheumNow ( View Tweet)
Hypertension Associated with RA and OA
Analysis of NHANES data suggests that both rheumatoid arthritis (RA) and osteoarthritis (OA) are strongly associated with hypertension (HTN).
https://t.co/HUWUvOKcMw https://t.co/6GkeEWQP40
Links:
Dr. John Cush RheumNow ( View Tweet)
Genetic Testing for Autoinflammatory Disease
Not all patients with periodic fevers fit neatly into diagnostic categories. Some can be diagnosed as Still’s disease (based on criteria) while others can be classified as AID and some may be unclassifiable.
https://t.co/E5qZS1JyAY https://t.co/PYgUbiduPF
Links:
Dr. John Cush RheumNow ( View Tweet)
Nintedinib has been studied in 39 children (6–17 yrs) with fibrosing ILD demonstrating pharmacokinetics (wt based dosing) and safety. Adjusted mean changes in FVC % at week 24 were 0.3 with nintedanib and −0.9 with placebo https://t.co/yQ7OREzpTR https://t.co/iylG9BZiz4
Links:
Dr. John Cush RheumNow ( View Tweet)
B12 or Placebo effect? Open label study of B12 (1000mcg/d) in 29 fibromyalgia pts showed after 50d, significant reductions in FM Impact Quest. (FIQR; 49.8 to 40.00; p< 0.01), Function, Sxs, anxiety scores all signif improved. https://t.co/MtJWy5xlz9 https://t.co/kzvA1wd3zb
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved SPEVIGO® (spesolimab-sbzo) an IV injection - the first-approved treatment option for generalized pustular psoriasis (GPP) FLARES. Spesolimab is an interleukin-36 receptor antagonist. https://t.co/izmExVCvfQ https://t.co/FELKR70UMv
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.
https://t.co/JqzZRu2HYR https://t.co/XefaHown4g https://t.co/XiMyDLhKIe
Dr. John Cush RheumNow ( View Tweet)
Risk of TNFi-related psoriasis in 5088 TNFi Rx children w/ IBD, JIA, or CNO. Compared to non-TNFi exposed, kids on TNFi had an increased PSO risk w/ ADA (IRR 2.70; 1.53-4.75), infliximab (2.34) or etanercept (2.21) & not incr w/ DMARD use https://t.co/Y1Vn9kjk5N https://t.co/5CCxa5kMcU
Links:
Dr. John Cush RheumNow ( View Tweet)
A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO
Sponsored by Lilly USA
Listen to Philip Mease and April Armstrong discuss a multidisciplinary approach and importantconsiderations when treating patients with joint and
skin concerns.
https://t.co/lTfz2kUr51
Links:
Dr. John Cush RheumNow ( View Tweet)
NICE Guidelines on Gout Diagnosis and Management
NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness.
https://t.co/a8iyCe3szJ https://t.co/6Jy7dOT4yX
Links:
Dr. John Cush RheumNow ( View Tweet)
Gout: diagnosis and management—summary of NICE guidance https://t.co/tVHkSMusk6 https://t.co/A7U1DlI7tO
Links:
Dr. John Cush RheumNow ( View Tweet)
SURPRISED? Psoriasis pts have a known increased risk of CV disease. But did you know several papers & metanalyses show increased risk of abdominal aortic aneurysm in PSO (HR 1.30), worse w/ dz activity; lost w/ age, female, DM? https://t.co/9ihyubUgCI https://t.co/W1JiXV0yOX https://t.co/Nq6aVBjPuK
Dr. John Cush RheumNow ( View Tweet)
Review of IL-1 inhibitors in recurrent idiopathic pericarditis. While Rilonacept is FDA approved (320 mg x1 then 160 mg sc/wk), anakinra (2 mg/kg/d or 100 mg/d), canakinumab and colchicine are used https://t.co/j00yWpBbq3 https://t.co/7BK2mopssc
Links:
Dr. John Cush RheumNow ( View Tweet)
USPSTF recommends clinicians prescribe Statins for the primary CVD prevention in adults (40-75 yrs) w/ 1 or more CVD risk factors (ie, dyslipidemia, DM, HTN, smoking) & 10-year CVD risk of 10% or greater. Inflammatory dz is considered a CV risk enhancer https://t.co/1Opblbiz7B https://t.co/xSw2uPUoKK
Links:
Dr. John Cush RheumNow ( View Tweet)
Review of steroids & immunosuppressants on cancer outcomes in checkpoint inhibitor therapy
- Steroid use "for irAEs may not have a large deleterious effect on overall survival"
- DMARDs for irAE "a major drawback in the delay in the onset of response"
https://t.co/8o8JBMpqML https://t.co/bWuLT3zYPm
Links:
Dr. John Cush RheumNow ( View Tweet)
MIRROR study lead to pegloticase (PEG) label change - adding MTX as Rx to reduced anti-PEG Abs. Based on 14 refractory gout pts given MTX 15mg/wk (w/ folate) and then PEG IV: 3 nonresponders, 1 dropped out, 10 responded/stayed on Rx x 52 wks w/ less ADAbs https://t.co/BZwY7DpmIb https://t.co/gNhhuhmTG5
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.
https://t.co/ZaWnjxiR3W https://t.co/8CElIxWk1v https://t.co/ZVayc3Qt1r
Dr. John Cush RheumNow ( View Tweet)